{"id":"the-treatment-of-investigator-choice","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"While the exact mechanism is not well understood, it is believed to involve a complex interplay of molecular pathways and cellular responses.","oneSentence":"The treatment of investigator choice works by targeting the underlying cause of the disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:23.219Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT05639647","phase":"PHASE2","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-04-18","conditions":"Gram-negative Bacterial Infections","enrollment":48},{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06781125","phase":"PHASE1, PHASE2","title":"One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2026-03-18","conditions":"Malignant Solid Tumors","enrollment":72},{"nctId":"NCT07489274","phase":"PHASE4","title":"Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial.","status":"NOT_YET_RECRUITING","sponsor":"Ole Hyldegaard","startDate":"2027-04-01","conditions":"Necrotizing Soft Tissue Infection","enrollment":1480},{"nctId":"NCT06780670","phase":"PHASE2, PHASE3","title":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-27","conditions":"Prostate Cancer","enrollment":443},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07435649","phase":"NA","title":"Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection","status":"NOT_YET_RECRUITING","sponsor":"Delve Bio, Inc.","startDate":"2026-03-01","conditions":"Central Nervous System Infection","enrollment":400},{"nctId":"NCT06532370","phase":"NA","title":"Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii","status":"COMPLETED","sponsor":"Queen's Medical Center","startDate":"2024-10-10","conditions":"Contingency Managment, Methamphetamine Use Disorder","enrollment":20},{"nctId":"NCT06738355","phase":"NA","title":"PREVENT Pilot HPV - Related Cancers Trial","status":"COMPLETED","sponsor":"University of Utah","startDate":"2025-05-20","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":335},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT06097962","phase":"EARLY_PHASE1","title":"Safety and Efficacy of NK510 to Treat NSCLC","status":"RECRUITING","sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-07-01","conditions":"NSCLC","enrollment":12},{"nctId":"NCT07486011","phase":"NA","title":"Effects of Osteopathic Treatment in Patients With Somatosensory Tinnitus","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2022-09-02","conditions":"Tinnitus","enrollment":54},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","enrollment":303},{"nctId":"NCT05235061","phase":"NA","title":"HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) -Post-Traumatic Epilepsy (PTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2022-03-21","conditions":"Epilepsy, Traumatic, Brain Injuries, Traumatic","enrollment":160},{"nctId":"NCT05388812","phase":"NA","title":"Together in Recovery With Veterans Through Employment","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-12-16","conditions":"Veterans With Opioid Use Disorder","enrollment":123},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT07483034","phase":"NA","title":"Receptive Music Therapy Effects on Anxiety, Depression, QoL, and EGF, IL-8, and NfL During the Breast Cancer Treatment.","status":"ENROLLING_BY_INVITATION","sponsor":"Brigita Vilc","startDate":"2024-10-01","conditions":"Breast Cancer Invasive, Chemotherapy, Breast Cancer Surgery","enrollment":90},{"nctId":"NCT06782100","phase":"","title":"MRI Guided Management of Occlusive Peripheral Arterial Disease","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-07-01","conditions":"Peripheral Vascular Diseases","enrollment":175},{"nctId":"NCT05605574","phase":"NA","title":"Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":222},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT05578300","phase":"","title":"Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-10-21","conditions":"Ischemic Stroke, Stroke, Stroke, Acute","enrollment":350},{"nctId":"NCT05629585","phase":"PHASE3","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-28","conditions":"Breast Cancer","enrollment":1174},{"nctId":"NCT03070392","phase":"PHASE2","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Immunocore Ltd","startDate":"2017-10-16","conditions":"Uveal Melanoma","enrollment":378},{"nctId":"NCT01019343","phase":"NA","title":"Physiological Investigations of Movement Disorders","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2009-12-08","conditions":"Parkinson's Disease, Tourette's Syndrome, Tic Disorders","enrollment":1273},{"nctId":"NCT07477184","phase":"NA","title":"Sleep Well Firefighters: An App-based Program to Improve Sleep, Cognition, and Behavioral Health in Firefighters","status":"RECRUITING","sponsor":"California Polytechnic State University-San Luis Obispo","startDate":"2026-01-05","conditions":"Sleep Health, Stress, Anxiety","enrollment":50},{"nctId":"NCT06072781","phase":"PHASE3","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2024-03-18","conditions":"Low Grade Serous Ovarian Cancer","enrollment":270},{"nctId":"NCT07475949","phase":"PHASE3","title":"Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":352},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT05390541","phase":"NA","title":"Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2022-02-02","conditions":"Hiv, Sexually Transmitted Diseases, Economic Problems","enrollment":3},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT05908734","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":71},{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT07468305","phase":"NA","title":"SENS'REM - SENSoriality and Multi-Sensory Emotional Reminiscences: a Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2026-07","conditions":"Apathy, Apathy in Dementia","enrollment":10},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT07123077","phase":"NA","title":"Functional Exercises With Turkish Music in Mild Dementia","status":"COMPLETED","sponsor":"Medipol University","startDate":"2025-02-01","conditions":"Mild Dementia, Music Therapy","enrollment":40},{"nctId":"NCT07461402","phase":"NA","title":"Plant Protein With Ashwagandha-Rhodiola for Sleep Quality","status":"COMPLETED","sponsor":"Universidad Pablo de Olavide","startDate":"2025-11-01","conditions":"Sleep Quality, Sleep Disorders, Insomnia","enrollment":100},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT07458230","phase":"PHASE3","title":"Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2026-05-01","conditions":"Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation","enrollment":250},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT07217145","phase":"NA","title":"PREVENT HPV -Related Cancers Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2025-10-09","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":1455},{"nctId":"NCT07252674","phase":"","title":"Comparison of Laryngeal Mask Airway and Endotracheal Intubation on Mechanical Power in Pediatric Patients","status":"RECRUITING","sponsor":"Konya City Hospital","startDate":"2025-11-30","conditions":"Mechanical Power","enrollment":100},{"nctId":"NCT07455019","phase":"PHASE2","title":"A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"Esophageal Cancer","enrollment":28},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT07452822","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","startDate":"2026-02-20","conditions":"Arteriovenous Fistula Stenosis","enrollment":54},{"nctId":"NCT06952101","phase":"NA","title":"A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2024-04-30","conditions":"Rectal Adenocarcinoma, Non Metastatic","enrollment":200},{"nctId":"NCT05934448","phase":"PHASE2","title":"Pembro Plus CAR T-cell Therapy in R/R in PMBCL","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-11-15","conditions":"Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT06722846","phase":"","title":"Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study.","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-21","conditions":"Health Options, Strategic Care Planning","enrollment":400},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT06803680","phase":"PHASE1","title":"A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2025-03-18","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":90},{"nctId":"NCT03133728","phase":"","title":"Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-05-30","conditions":"HIV Infections, Hiv","enrollment":1682},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT07166094","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","status":"RECRUITING","sponsor":"Genmab","startDate":"2025-11-28","conditions":"Endometrial Cancer, Recurrent or Progressive Endometrial Cancer","enrollment":544},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT07310784","phase":"PHASE2","title":"A Phase II Trial of LM103 in Advanced Melanoma","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2025-12-16","conditions":"Advanced Melanoma","enrollment":92},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT02476812","phase":"NA","title":"The Positive Piggy Bank - A Positive Activities Intervention for Improving Functional Status in Patients With Back Pain","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-06","conditions":"Low Back Pain","enrollment":200},{"nctId":"NCT07441512","phase":"PHASE2","title":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","status":"NOT_YET_RECRUITING","sponsor":"Hu Hai","startDate":"2026-03-15","conditions":"TNBC - Triple-Negative Breast Cancer, TNBC","enrollment":26},{"nctId":"NCT04667078","phase":"PHASE3","title":"REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-03-02","conditions":"Acute Ischemia","enrollment":368},{"nctId":"NCT06510556","phase":"NA","title":"Feasibility Study of the FARAFLEX Mapping and PFA System","status":"RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2025-02-17","conditions":"Atrial Fibrillation, Persistent Atrial Fibrillation, Paroxysmal AF","enrollment":250},{"nctId":"NCT06086626","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2024-03-14","conditions":"Gram-Negative Bacterial Infections","enrollment":30},{"nctId":"NCT07444372","phase":"NA","title":"Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-04-15","conditions":"Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF)","enrollment":658},{"nctId":"NCT07442019","phase":"NA","title":"Fear, Emotional Behaviors and Parental Care Satisfaction Related to Inhalation Therapy","status":"COMPLETED","sponsor":"Karamanoğlu Mehmetbey University","startDate":"2024-01-01","conditions":"Child, Only, Fear, Pediatric Nursing","enrollment":120},{"nctId":"NCT07440160","phase":"NA","title":"Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arba Minch University","startDate":"2025-07-01","conditions":"Tuberculosis","enrollment":278},{"nctId":"NCT05192590","phase":"NA","title":"Establishing Clinical Utility Evidence for Chronic Disease Management Testing","status":"COMPLETED","sponsor":"Qure Healthcare, LLC","startDate":"2021-10-22","conditions":"Cardiometabolic Syndrome","enrollment":247},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT04335539","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2020-08-21","conditions":"Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI)","enrollment":53},{"nctId":"NCT05855746","phase":"PHASE3","title":"Colchicine Versus Placebo in Acute Myocarditis Patients","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-07-16","conditions":"Acute Myocarditis","enrollment":300},{"nctId":"NCT07433296","phase":"NA","title":"THE EFFECT OF SANDPLAY THERAPY ON THE ANXİETY AND PAİN LEVELS OF CHİLDREN DURİNG PREOPERATİVE PERİOD","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2024-10-01","conditions":"Tonsillectomy, Postoperative Pain, Preoperative Anxiety","enrollment":68},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT07433075","phase":"NA","title":"Assessment of the Clinical and Economic Impact of Sim&Size, a Simulation Software for Implantable Devices Used in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study.","status":"NOT_YET_RECRUITING","sponsor":"Sim&Cure","startDate":"2026-03","conditions":"Unruptured Intracranial Aneurysm","enrollment":576},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT06972303","phase":"PHASE1, PHASE2","title":"Mindfulness Meditation for Insomnia","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02","conditions":"Sleep Initiation and Maintenance Disorders, Insomnia, Insomnia Chronic","enrollment":30},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT07119112","phase":"NA","title":"Evaluation of a Novel Drain Stripping Device for Reducing Surgical Drain Complications","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2026-02-20","conditions":"Surgical Drain, Abdominal Surgery Patients, Drains","enrollment":500},{"nctId":"NCT01171898","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2010-07-26","conditions":"Prostate Cancer","enrollment":127},{"nctId":"NCT07209917","phase":"NA","title":"Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2026-02-01","conditions":"Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection","enrollment":420},{"nctId":"NCT05780814","phase":"NA","title":"The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-01","conditions":"Breast Cancer, Insomnia, Weight Gain","enrollment":250},{"nctId":"NCT07418515","phase":"NA","title":"Impact of Therapeutic Storytelling on Fear, Screen Time, and Parental Stress Among Hospitalized Children","status":"COMPLETED","sponsor":"Karabuk University","startDate":"2024-06-01","conditions":"Hospitalized Children, Parent Stress","enrollment":44},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT04912531","phase":"NA","title":"Virtual Reality and Olfactory Stimuli Multimodal Intervention to Reduce Post-Operative Pain and Anxiety in Patients Undergoing Cardiothoracic Surgery","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-10-01","conditions":"Postoperative Pain, Anxiety Postoperative, Opioid Use","enrollment":80},{"nctId":"NCT05832177","phase":"","title":"Outreach Core Activities","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-03-22","conditions":"Cancer Education, Spanish Language Cancer Education","enrollment":1200},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07417735","phase":"PHASE3","title":"SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-03-18","conditions":"Locally Advanced/Metastatic/Recurrent ESCC","enrollment":436},{"nctId":"NCT07326215","phase":"NA","title":"A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2025-12-11","conditions":"Acute Respiratory Distress Syndrome, Acute Kidney Injury","enrollment":99},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07408505","phase":"NA","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-20","conditions":"Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"The treatment of investigator choice","genericName":"The treatment of investigator choice","companyName":"LintonPharm Co.,Ltd.","companyId":"lintonpharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The treatment of investigator choice works by targeting the underlying cause of the disease. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}